Product was Karyopharm Therapeutics’s largest product and service line in fiscal 2025, bringing in $114.86M of $148.17M (78%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Product | $120.45M | $112.01M | $112.81M | $114.86M | ||||
| Product Revenue | — | — | — | — | ||||
| License & Other Revenue | $36.63M | $34.02M | $32.43M | $31.21M | ||||
| Royalty | $300.00K | $1.10M | $1.70M | $2.10M | ||||
| Total | $157.37M | $147.13M | $146.94M | $148.17M |
Karyopharm Therapeutics brought in $148.17M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 0.8% from $146.94M in fiscal 2024. Product was the largest at $114.86M (77.5%), ahead of License & Other Revenue at $31.21M (21.1%) and Royalty at $2.10M (1.4%).
Compared with fiscal 2024, Product grew 1.8% to $114.86M, while License & Other Revenue fell 3.8% to $31.21M. From fiscal 2022 to 2025, combined revenue from these lines fell from $157.37M to $148.17M, a compound annual decline of 2.0%. Product's share of the total rose from 76.5% to 77.5%.
Karyopharm Therapeutics (KPTI) reports its revenue by product and service. In fiscal 2025, Product was its largest product and service line, bringing in $114.86M (77.5% of the total), followed by License & Other Revenue at $31.21M (21.1%).
Product was Karyopharm Therapeutics' largest product and service line in fiscal 2025, bringing in $114.86M, or 77.5% of the $148.17M total across its three product and service lines.
Product grew faster than License & Other Revenue in fiscal 2025, up 1.8% from $112.81M to $114.86M. License & Other Revenue fell 3.8% to $31.21M.
Every figure comes from Karyopharm Therapeutics' annual financial filings, as reported. Each line keeps the name Karyopharm Therapeutics gives it, and years follow its fiscal calendar.
Karyopharm Therapeutics' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.